Doug Fambrough | President and Chief Executive Officer |
Bob Brown | Chief Scientific Officer and Executive Vice President, R&D |
Man-Fung Yuen | Chair Professor, Gastroenterology and Hepatology, Li Shu Fan Medical Foundation, Professor, Medicine, Chief of the Division of Gastroenterology and Hepatology, Deputy Head, Department of Medicine, University of Hong Kong |
Bernd Hoppe | Vice President and Global Head Medical Affairs, Head, German Hyperoxaluria Center, Professor, Pediatrics, University of Cologne |
Ralph Rosskamp | Chief Medical Officer |
Rob Ciappenelli | Chief Commercial Officer |
Mani Foroohar | SVB Leerink |
Jonathan Miller | Evercore |
Stephen Willey | Stifel |
Samantha Semenkow | Citi |
Luca Issi | RBC |
Brendan Smith | Cowen |
Nicole Germino | SunTrust Robinson Humphrey |
Ed Arce | H.C. Wainwright |
Madhu Kumar | Baird |
Good morning, everyone and welcome to Dicerna 2020 Virtual R&D Day.
As you know we also issued a press release this morning detailing our Financial Results for the Second Quarter ended June 30 2020, which can be found under the Investors and Media tab on our website at dicerna.com.
During this morning's presentation, we will be reviewing data results from our ongoing studies of RG6346 in collaborative development with Roche for hepatitis B, and nedosiran for the treatment of primary hyperoxaluria.
We are also excited to share with you the initial preclinical data from our RNAi technology and extrahepatic tissue including the CNS, muscle and adipose tissues. I'd like to remind listeners as noted in today's presentation that management may be making forward-looking statements on today's call, including, for example, the clinical development, therapeutic or potential of nedosiran or RG6346 and the development programs, research and development plans and timelines, the potential for Dicerna to continue to add programs and extend the reach of our technology to additional tissues in our internal discovery research and in collaborative programs.